Seoul: The distribution division of South Korean biotechnology company Celltrion has signed contracts to supply monoclonal antibodies to treat COVID-19 with nine European countries, Celltrion Healthcare said Tuesday.
The European Commission approved the company’s antibody therapy Regirona earlier this month, granting marketing approval to adults with COVID-19 who are at high risk of developing a severe condition.
Celltrion said in a statement that the first batch of 50,000 batches was shipped to Europe this year and the company is in talks with 47 other countries, including Asia, Latin America and the Middle East.
Antibody treatment was first approved in South Korea and was administered to approximately 25,000 local COVID-19 patients as of last week.
Laboratory-produced monoclonal antibodies mimic natural antibodies in combating infection. Unlike vaccines, it does not depend on the body to produce an immune response, so it can help individuals with weak or impaired immune systems.
(Report by Sangmi Cha, edited by Richard Pullin)
Celltrion signs supply contract for COVID-19 antibody therapy with Europe, Health News, ET Health World
Source link Celltrion signs supply contract for COVID-19 antibody therapy with Europe, Health News, ET Health World